JP4896327B2
(ja)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
Pd−1、b7−4の受容体、およびその使用
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
US7030219B2
(en)
*
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
ES2654064T3
(es)
*
|
2002-07-03 |
2024-03-13 |
Ono Pharmaceutical Co |
Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
|
EP1539228B1
(en)
|
2002-09-11 |
2010-12-29 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
AU2005295038B2
(en)
|
2004-10-06 |
2012-05-17 |
Mayo Foundation For Medical Education And Research |
B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
|
CN101213297B
(zh)
*
|
2005-05-09 |
2013-02-13 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
|
US20070054360A1
(en)
|
2005-05-12 |
2007-03-08 |
Zeren Gao |
Compositions and methods for modulating immune responses
|
CA2981431C
(en)
*
|
2005-06-08 |
2021-04-13 |
Dana-Farber Cancer Institute Inc. |
Use of compounds that reduce activity or expression of programmed cell death-1 to treat lymphoma
|
AU2012204032B2
(en)
*
|
2005-06-08 |
2014-01-16 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
CN101501062B
(zh)
*
|
2005-07-26 |
2012-07-18 |
康哲医药研究(深圳)有限公司 |
新型生物活性肽及其新用途
|
EP1777523A1
(en)
*
|
2005-10-19 |
2007-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
JP5093097B2
(ja)
|
2006-03-03 |
2012-12-05 |
小野薬品工業株式会社 |
細胞表面機能分子の細胞外領域多量体
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
WO2007143139A1
(en)
|
2006-05-31 |
2007-12-13 |
The Brigham And Women's Hospital, Inc. |
Abcb5 positive mesenchymal stem cells as immunomodulators
|
US20090304711A1
(en)
*
|
2006-09-20 |
2009-12-10 |
Drew Pardoll |
Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
|
PT2486941T
(pt)
|
2006-10-02 |
2017-05-30 |
Squibb & Sons Llc |
Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
|
EP2133365B1
(en)
*
|
2006-12-27 |
2017-05-17 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
LT2644205T
(lt)
|
2007-04-12 |
2018-12-10 |
The Brigham And Women`S Hospital, Inc. |
Nutaikymas į abcb5 vėžio terapijai
|
KR101586617B1
(ko)
*
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 pd-1에 대한 항체
|
WO2009029342A2
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
HUE034465T2
(hu)
|
2008-02-11 |
2018-02-28 |
Cure Tech Ltd |
Monoklonális antitestek tumor kezelésére
|
US20110020325A1
(en)
*
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
EP2262837A4
(en)
*
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
SG10201402815VA
(en)
|
2008-04-09 |
2014-09-26 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
EP2288379A4
(en)
|
2008-05-19 |
2012-08-08 |
Advaxis |
DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
|
WO2010001617A1
(en)
*
|
2008-07-04 |
2010-01-07 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CN102203125A
(zh)
*
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
|
PT3130923T
(pt)
*
|
2008-11-14 |
2020-06-17 |
Brigham & Womens Hospital Inc |
Métodos terapêuticos relacionados com células estaminais
|
US11542328B2
(en)
|
2008-11-14 |
2023-01-03 |
The Brigham And Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
HUE028582T2
(hu)
|
2008-11-28 |
2016-12-28 |
Univ Emory |
Eljárás PD-1 antagonisták hatásosságának meghatározására
|
PE20120341A1
(es)
*
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
CN107090437A
(zh)
|
2009-03-06 |
2017-08-25 |
国立大学法人三重大学 |
用于增强t细胞功能的方法
|
EP2482849B1
(en)
*
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CA2802344C
(en)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
US8907053B2
(en)
*
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
JP5981436B2
(ja)
|
2010-10-01 |
2016-08-31 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
|
CN103517990A
(zh)
|
2010-10-07 |
2014-01-15 |
通用医疗公司 |
癌症生物标志物
|
EP3332804A1
(en)
|
2011-03-11 |
2018-06-13 |
Advaxis, Inc. |
Listeria-based adjuvants
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind B7-H1 and PD-1
|
CN102250910B
(zh)
*
|
2011-05-31 |
2013-01-30 |
苏州大学 |
一种人可溶性b7-dc定量检测试剂盒
|
EP2717895A1
(en)
*
|
2011-06-08 |
2014-04-16 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
PL3351261T3
(pl)
|
2011-10-11 |
2021-12-06 |
Universität Zürich |
Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
CN103917243B
(zh)
*
|
2011-10-17 |
2021-05-11 |
Io生物技术公司 |
基于pd-l1的免疫疗法
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
CN103826627B
(zh)
|
2011-10-21 |
2016-02-24 |
艾伯维公司 |
包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
|
WO2013059638A1
(en)
|
2011-10-21 |
2013-04-25 |
Abbvie Inc. |
Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
|
RS61033B1
(sr)
|
2011-11-28 |
2020-12-31 |
Merck Patent Gmbh |
Antitela na pd-l1 i njihova upotreba
|
GB201120779D0
(en)
|
2011-12-02 |
2012-01-11 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
US20150004175A1
(en)
*
|
2011-12-13 |
2015-01-01 |
Yale University |
Compositions and Methods for Reducing CTL Exhaustion
|
ES2694180T3
(es)
*
|
2012-01-20 |
2018-12-18 |
Vib Vzw |
Citocinas de haz alfa-helicoidal mutantes dirigidas
|
NZ628206A
(en)
|
2012-02-16 |
2016-03-31 |
Vlp Therapeutics Llc |
Virus like particle composition
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
BR112014022662A2
(pt)
|
2012-03-12 |
2017-10-03 |
Advaxis Inc |
Inibição da função de célula supressora seguindo tratamento de vacina de listeria
|
CN104245726A
(zh)
*
|
2012-03-29 |
2014-12-24 |
奥瑞基尼探索技术有限公司 |
来自人pd1的bc环的免疫调节环状化合物
|
WO2013155493A1
(en)
|
2012-04-12 |
2013-10-17 |
Yale University |
Methods of treating inflammatory and autoimmune diseases and disorders
|
BR122022015975B1
(pt)
|
2012-05-15 |
2024-01-02 |
Bristol-Myers Squibb Company |
Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
|
WO2013176916A1
(en)
*
|
2012-05-25 |
2013-11-28 |
Roman Galetto |
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
CN112587671A
(zh)
*
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
EP2950814A4
(en)
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF
|
US20150368316A1
(en)
*
|
2013-02-07 |
2015-12-24 |
Albert Einstein College Of Medicine Of Yeshiva University |
A selective high-affinity immune stimulatory reagent and uses thereof
|
EP2954327A1
(en)
|
2013-02-07 |
2015-12-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
|
BR112015018989B1
(pt)
|
2013-02-22 |
2023-11-14 |
Curevac Ag |
Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
RU2015147696A
(ru)
|
2013-04-09 |
2017-05-12 |
Бостон Байомедикал, Инк. |
Способы лечения злокачественной опухоли
|
LT2992017T
(lt)
|
2013-05-02 |
2021-02-25 |
Anaptysbio, Inc. |
Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1)
|
CN103242448B
(zh)
*
|
2013-05-27 |
2015-01-14 |
郑州大学 |
一种全人源化抗pd-1单克隆抗体及其制备方法和应用
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
US9637532B2
(en)
|
2013-07-12 |
2017-05-02 |
Vlp Therapeutics, Llc |
Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
|
WO2015009856A2
(en)
|
2013-07-16 |
2015-01-22 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
CA2922655A1
(en)
|
2013-09-06 |
2015-03-12 |
Aurigene Discovery Technologies Limited |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
JP6521977B2
(ja)
|
2013-09-06 |
2019-05-29 |
オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited |
免疫調節剤としての1,2,4−オキサジアゾール誘導体
|
HUE039012T2
(hu)
|
2013-09-06 |
2018-12-28 |
Aurigene Discovery Tech Ltd |
Gyûrûs peptidomimetikus vegyületek, mint immunomodulátorok
|
MX2016003292A
(es)
|
2013-09-13 |
2016-06-24 |
Beigene Ltd |
Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos.
|
BR122023024195A2
(pt)
|
2013-09-20 |
2023-12-26 |
Bristol-Myers Squibb Company |
Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
KR20190126452A
(ko)
|
2013-11-01 |
2019-11-11 |
예일 유니버시티 |
면역요법용 모듈러 입자
|
LT3081576T
(lt)
|
2013-12-12 |
2019-10-25 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
US10106607B2
(en)
|
2013-12-20 |
2018-10-23 |
Intervet Inc. |
Caninized antibodies
|
GB201322725D0
(en)
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
HRP20220748T1
(hr)
|
2013-12-24 |
2022-09-02 |
Janssen Pharmaceutica Nv |
Anti-vista antitijela i fragmenti
|
US10548985B2
(en)
|
2014-01-10 |
2020-02-04 |
Birdie Biopharmaceuticals, Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
HUE057917T2
(hu)
*
|
2014-01-15 |
2022-06-28 |
Kadmon Corp Llc |
Immunmodulátor szerek
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CA2938566A1
(en)
|
2014-02-04 |
2015-08-13 |
Incyte Corporation |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
TR201901507T4
(tr)
|
2014-02-04 |
2019-02-21 |
Merck Sharp & Dohme |
Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu.
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
KR102248804B1
(ko)
|
2014-03-12 |
2021-05-11 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
CA2947939A1
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
PL3148579T3
(pl)
|
2014-05-28 |
2021-07-19 |
Agenus Inc. |
Przeciwciała anty-gitr i sposoby ich zastosowania
|
CA2951885C
(en)
|
2014-06-11 |
2023-07-04 |
Kathy A. Green |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
JP6279733B2
(ja)
|
2014-07-09 |
2018-02-14 |
日本全薬工業株式会社 |
抗イヌpd−1抗体又は抗イヌpd−l1抗体
|
EP3166976B1
(en)
|
2014-07-09 |
2022-02-23 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
KR102504758B1
(ko)
|
2014-07-16 |
2023-02-28 |
트랜스진 |
종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물
|
CA3190510A1
(en)
|
2014-07-16 |
2016-01-21 |
Transgene Sa |
Oncolytic virus for expression of immune checkpoint modulators
|
WO2016011357A1
(en)
|
2014-07-18 |
2016-01-21 |
Advaxis, Inc. |
Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
|
AU2015292678B2
(en)
|
2014-07-22 |
2020-10-22 |
Cb Therapeutics, Inc. |
Anti-PD-1 antibodies
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
EP3195168B1
(en)
*
|
2014-07-31 |
2022-09-07 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
ES2847311T3
(es)
|
2014-08-05 |
2021-08-02 |
MabQuest SA |
Reactivos inmunológicos que se unen a PD-1
|
CA2956399A1
(en)
|
2014-08-05 |
2016-02-11 |
Cb Therapeutics, Inc. |
Anti-pd-l1 antibodies
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
CA2957387A1
(en)
|
2014-08-07 |
2016-02-11 |
Hyogo College Of Medicine |
Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
|
US10385101B2
(en)
|
2014-08-08 |
2019-08-20 |
Vlp Therapeutics, Llc |
Virus like particle comprising modified envelope protein E3
|
WO2016021209A1
(en)
|
2014-08-08 |
2016-02-11 |
Vlp Therapeutics, Llc |
Virus like particle comprising modified envelope protein e3
|
EP3232199B1
(en)
*
|
2014-08-19 |
2022-05-04 |
National University Corporation Okayama University |
Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer
|
US10695426B2
(en)
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
KR102532832B1
(ko)
|
2014-09-11 |
2023-05-16 |
브이엘피 테라퓨틱스 인코포레이티드 |
플라비바이러스 바이러스 유사 입자
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
CN107074952B
(zh)
|
2014-09-30 |
2021-04-09 |
英特维特国际股份有限公司 |
结合犬pd-l1的pd-l1抗体
|
US10039564B2
(en)
|
2014-09-30 |
2018-08-07 |
Ethicon Llc |
Surgical devices having power-assisted jaw closure and methods for compressing and sensing tissue
|
MX2017004708A
(es)
|
2014-10-10 |
2017-10-12 |
Idera Pharmaceuticals Inc |
Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
|
BR112017007379A2
(pt)
|
2014-10-14 |
2017-12-19 |
Dana Farber Cancer Inst Inc |
moléculas de anticorpo para pd-l1 e usos das mesmas
|
JP7305300B2
(ja)
|
2014-11-05 |
2023-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
併用免疫療法
|
SG11201703925VA
(en)
*
|
2014-12-02 |
2017-06-29 |
Celgene Corp |
Combination therapies
|
WO2016089833A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
WO2016089830A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
WO2016089797A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
WO2016094273A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
AU2015360667B2
(en)
*
|
2014-12-09 |
2021-09-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized cluster of differentiation 274 gene
|
JP6767096B2
(ja)
*
|
2014-12-11 |
2020-10-14 |
リティックス バイオファーマ エイエス |
免疫チェックポイント阻害剤の組み合わせ
|
JPWO2016104657A1
(ja)
|
2014-12-26 |
2017-10-12 |
株式会社セラバイオファーマ |
癌治療剤
|
ES2856844T3
(es)
|
2014-12-31 |
2021-09-28 |
Checkmate Pharmaceuticals Inc |
Inmunoterapia antitumoral combinada
|
GB201500319D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
GB201500374D0
(en)
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
EP3252469A1
(en)
*
|
2015-01-29 |
2017-12-06 |
Konica Minolta, Inc. |
Method for simultaneous detection of blood cells having interacting molecules
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
CN107635582B
(zh)
*
|
2015-02-12 |
2022-08-02 |
约翰·霍普金斯大学 |
用于阻断肿瘤免疫耐受性的yap抑制
|
CN107405401B
(zh)
|
2015-02-26 |
2022-02-01 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
CA2978311A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating cancer
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
EP3267984B1
(en)
|
2015-03-10 |
2021-11-24 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
US10336824B2
(en)
|
2015-03-13 |
2019-07-02 |
Cytomx Therapeutics, Inc. |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
|
EA037621B1
(ru)
|
2015-03-23 |
2021-04-22 |
Джаунс Терапьютикс, Инк. |
Антитела к icos
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
EP3283107B1
(en)
|
2015-04-17 |
2020-05-27 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of ipilimumab and nivolumab
|
WO2016176503A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
CN108368147A
(zh)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
用于治疗癌症的核苷酸
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
AU2016271018A1
(en)
|
2015-05-29 |
2017-11-30 |
Dynavax Technologies Corporation |
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
|
CN113603784A
(zh)
|
2015-05-29 |
2021-11-05 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
RU2017145940A
(ru)
*
|
2015-05-29 |
2019-07-02 |
Дайнэвокс Текнолоджиз Корпорейшн |
Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких
|
AU2016271475A1
(en)
|
2015-06-03 |
2017-12-21 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
JP2018524299A
(ja)
*
|
2015-06-12 |
2018-08-30 |
マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル |
免疫応答を調節するための方法およびポリペプチド
|
KR20180018762A
(ko)
|
2015-06-16 |
2018-02-21 |
메르크 파텐트 게엠베하 |
Pd-l1 길항제 조합 치료
|
PT3319635T
(pt)
*
|
2015-06-24 |
2021-07-07 |
Immodulon Therapeutics Ltd |
Um inibidor de ponto de verificação e uma micobactéria de célula inteira para utilização em terapêutica do cancro
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
KR20180040138A
(ko)
|
2015-07-13 |
2018-04-19 |
싸이톰스 테라퓨틱스, 인크. |
항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
|
RS61532B1
(sr)
|
2015-07-14 |
2021-04-29 |
Bristol Myers Squibb Co |
Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
|
EP3744340A3
(en)
|
2015-07-16 |
2021-03-03 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
GEP20227419B
(en)
|
2015-07-30 |
2022-10-10 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
WO2017023753A1
(en)
|
2015-07-31 |
2017-02-09 |
University Of Florida Research Foundation, Inc. |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
EP3331918A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
RU2018107693A
(ru)
|
2015-08-04 |
2019-09-05 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Комбинированные виды лечения и их варианты применения и способы
|
KR20180035906A
(ko)
|
2015-08-07 |
2018-04-06 |
피어이스 파마슈티컬즈 게엠베하 |
Lag-3 및 pd-1에 특이적인 신규 융합 폴리펩타이드
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
IL293385A
(en)
|
2015-08-11 |
2022-07-01 |
Omniab Inc |
New anti–pd–1 antibodies
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
MX2018002315A
(es)
|
2015-09-01 |
2018-04-11 |
Agenus Inc |
Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
|
ES2905554T3
(es)
|
2015-09-03 |
2022-04-11 |
Ono Pharmaceutical Co |
Agente para aumentar la inmunidad frente al cáncer utilizando antagonista de Alergina-1
|
US11124569B2
(en)
*
|
2015-09-18 |
2021-09-21 |
Dana-Farber Cancer Institute, Inc. |
Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
|
WO2017053250A1
(en)
*
|
2015-09-21 |
2017-03-30 |
Merck Sharp & Dohme Corp. |
Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof
|
CA2999756A1
(en)
*
|
2015-09-24 |
2017-03-30 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for reducing metastases
|
CA2994858C
(en)
|
2015-09-25 |
2024-01-23 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
US10981991B2
(en)
*
|
2015-09-29 |
2021-04-20 |
Shanghai Zhangjiang Biotechnology Co., Ltd. |
PD-1 antibodies and uses thereof
|
AR106184A1
(es)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
Proteínas de unión a pd-1 y sus métodos de uso
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
MY192202A
(en)
|
2015-10-02 |
2022-08-06 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
MX2018003629A
(es)
|
2015-10-02 |
2018-08-01 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso.
|
KR20180084772A
(ko)
|
2015-10-08 |
2018-07-25 |
마크로제닉스, 인크. |
암 치료를 위한 조합 치료법
|
US20180318365A1
(en)
|
2015-10-19 |
2018-11-08 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
WO2017070423A1
(en)
|
2015-10-22 |
2017-04-27 |
Jounce Therapeutics, Inc. |
Gene signatures for determining icos expression
|
CA3003252C
(en)
*
|
2015-10-28 |
2024-06-25 |
Yale University |
Humanized anti-dkk2 antibody and uses thereof
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
KR20180069070A
(ko)
|
2015-11-03 |
2018-06-22 |
얀센 바이오테크 인코포레이티드 |
Tim-3과 특이적으로 결합하는 항체 및 그의 용도
|
CA3003969A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
EP3373959B1
(en)
|
2015-11-12 |
2022-06-29 |
Hookipa Biotech GmbH |
Arenavirus particles as cancer vaccines
|
TWI795347B
(zh)
|
2015-11-18 |
2023-03-11 |
美商必治妥施貴寶公司 |
使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
|
US20190256608A1
(en)
|
2015-12-01 |
2019-08-22 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
US11447557B2
(en)
|
2015-12-02 |
2022-09-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
CR20180286A
(es)
|
2015-12-03 |
2018-07-16 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos de purina cíclicos como moduladores de sting
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
BR112018011781A2
(pt)
|
2015-12-14 |
2018-12-04 |
Macrogenics Inc |
molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
|
WO2017106062A1
(en)
|
2015-12-15 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
GB201522309D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
TWI747868B
(zh)
|
2016-01-08 |
2021-12-01 |
日商大鵬藥品工業股份有限公司 |
含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑
|
CN117679499A
(zh)
|
2016-01-10 |
2024-03-12 |
尼奥克斯医疗有限公司 |
用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
AU2017208819B2
(en)
|
2016-01-22 |
2023-10-19 |
MabQuest SA |
PD1 specific antibodies
|
US11661455B2
(en)
|
2016-02-05 |
2023-05-30 |
Orionis Biosciences BV |
Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
|
EP4059957A1
(en)
|
2016-02-05 |
2022-09-21 |
Orionis Biosciences BV |
Bispecific signaling agents and uses thereof
|
US10899836B2
(en)
|
2016-02-12 |
2021-01-26 |
Janssen Pharmaceutica Nv |
Method of identifying anti-VISTA antibodies
|
EP3213768A1
(en)
|
2016-03-01 |
2017-09-06 |
LODOCO CLINICAL Kft |
Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
US11975002B2
(en)
|
2016-03-04 |
2024-05-07 |
Taiho Pharmaceutical Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
WO2017153402A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
US20170252417A1
(en)
|
2016-03-07 |
2017-09-07 |
Massachusetts Institute Of Technology |
Protein-chaperoned t-cell vaccines
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
JP7208492B2
(ja)
|
2016-03-10 |
2023-01-19 |
シージー オンコロジー, インコーポレイテッド |
併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
|
KR102417646B1
(ko)
|
2016-03-14 |
2022-07-07 |
에프. 호프만-라 로슈 아게 |
Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
EP4302782A3
(en)
|
2016-03-15 |
2024-03-27 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
TWI762473B
(zh)
*
|
2016-03-30 |
2022-05-01 |
中天生物科技股份有限公司 |
以免疫檢測點調節劑以及由共生微生物菌叢之發酵產物的結合癌症療法
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
WO2017176925A1
(en)
|
2016-04-05 |
2017-10-12 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
EP3440076B1
(en)
|
2016-04-07 |
2022-06-01 |
GlaxoSmithKline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
US20210017281A1
(en)
|
2016-04-15 |
2021-01-21 |
Immunext, Inc. |
Anti-human vista antibodies and use thereof
|
JP7129703B2
(ja)
|
2016-04-28 |
2022-09-02 |
エモリー ユニバーシティー |
アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
|
WO2017191545A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
EP3455245A2
(en)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutic targeting of non-cellular structures
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン-ベータおよびその使用
|
WO2017201043A1
(en)
*
|
2016-05-16 |
2017-11-23 |
Concert Pharmaceuticals, Inc. |
Combination therapy for treating cancer
|
JP7267012B2
(ja)
|
2016-05-27 |
2023-05-01 |
アジェナス インコーポレイテッド |
抗tim-3抗体及びその使用方法
|
FI3466934T3
(fi)
|
2016-05-31 |
2024-04-23 |
Taiho Pharmaceutical Co Ltd |
Sulfonamidiyhdisteitä tai niiden suola ribonukleotidireduktaasin inhibiittoreina syövän hoitamiseksi
|
KR20230038318A
(ko)
|
2016-06-02 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단
|
FI3464368T3
(fi)
|
2016-06-02 |
2023-09-12 |
Bristol Myers Squibb Co |
Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa
|
KR102515509B1
(ko)
|
2016-06-03 |
2023-03-28 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
KR20190015407A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
|
JP2019521111A
(ja)
|
2016-06-08 |
2019-07-25 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Atf4経路阻害剤としての化学化合物
|
BR112018075615A2
(pt)
|
2016-06-08 |
2019-07-02 |
Glaxosmithkline Ip Dev Ltd |
compostos químicos
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
US9567399B1
(en)
*
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
DK3476865T3
(da)
|
2016-06-28 |
2023-12-18 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
|
SG11201811600PA
(en)
|
2016-06-30 |
2019-01-30 |
Oncorus Inc |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
AU2017293423B2
(en)
|
2016-07-05 |
2023-05-25 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
US20190241573A1
(en)
|
2016-07-20 |
2019-08-08 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
RU2757394C2
(ru)
|
2016-08-03 |
2021-10-14 |
Нексткьюр, Инк. |
Композиции и способы для модуляции передачи сигнала lair
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
TWI760352B
(zh)
|
2016-08-09 |
2022-04-11 |
英商克馬伯有限公司 |
抗icos抗體
|
DK3500299T3
(da)
|
2016-08-19 |
2024-01-29 |
Beigene Switzerland Gmbh |
Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
|
WO2018039131A1
(en)
*
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
US10372100B2
(en)
*
|
2016-08-29 |
2019-08-06 |
Ge Healthcare Bio-Sciences Corp. |
Manufacturing system for biopharmaceutical products
|
EP3858365B1
(en)
|
2016-09-01 |
2024-01-31 |
Chimera Bioengineering Inc. |
Gold optimized car t-cells
|
EP3778643A1
(en)
|
2016-09-14 |
2021-02-17 |
AbbVie Biotherapeutics Inc. |
Pharmaceutical uses of anti-pd-1(cd279) antibodies
|
WO2018053434A1
(en)
|
2016-09-16 |
2018-03-22 |
The Johns Hopkins University |
Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
|
KR102257154B1
(ko)
|
2016-09-19 |
2021-05-28 |
셀진 코포레이션 |
Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
EP4360714A2
(en)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
KR102644544B1
(ko)
|
2016-09-21 |
2024-03-11 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
JP2019537619A
(ja)
|
2016-09-27 |
2019-12-26 |
オンコロジー、インコーポレイテッド |
β2−糖タンパク質1のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ
|
SG10202008647TA
(en)
|
2016-10-04 |
2020-10-29 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
BR112019006504A2
(pt)
|
2016-10-06 |
2019-06-25 |
Merck Patent Gmbh |
regime de dosagem de avelumabe para o tratamento de câncer
|
MX2019003683A
(es)
|
2016-10-11 |
2019-08-22 |
Agenus Inc |
Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
|
JP2019530706A
(ja)
|
2016-10-14 |
2019-10-24 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
尿路上皮がんを治療するための、pd−1アンタゴニスト及びエリブリンの組合せ
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
EP3533869A4
(en)
|
2016-10-26 |
2020-06-10 |
Denka Company Limited |
MUTANT HUMAN EPSILON DNA POLYMERASE
|
AU2017354070A1
(en)
|
2016-11-01 |
2019-05-16 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (PD-1)
|
TW201829462A
(zh)
|
2016-11-02 |
2018-08-16 |
英商葛蘭素史克智慧財產(第二)有限公司 |
結合蛋白
|
WO2018085358A1
(en)
|
2016-11-02 |
2018-05-11 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
WO2018089688A1
(en)
|
2016-11-09 |
2018-05-17 |
Jinjun Shi |
Restoration of tumor suppression using mrna-based delivery system
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
EP3541825A1
(en)
|
2016-11-21 |
2019-09-25 |
Idenix Pharmaceuticals LLC. |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
EP3548071A4
(en)
|
2016-11-30 |
2020-07-15 |
OncoMed Pharmaceuticals, Inc. |
METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES
|
CN110248676A
(zh)
|
2016-12-01 |
2019-09-17 |
葛兰素史密斯克莱知识产权发展有限公司 |
组合疗法
|
JP2020511407A
(ja)
|
2016-12-01 |
2020-04-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
併用療法
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
MD3551660T2
(ro)
|
2016-12-07 |
2024-03-31 |
Agenus Inc |
Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
WO2018123999A1
(ja)
|
2016-12-28 |
2018-07-05 |
学校法人近畿大学 |
免疫チェックポイント阻害剤の投与対象となる個体の選択方法
|
ES2945745T3
(es)
|
2017-01-09 |
2023-07-06 |
Tesaro Inc |
Métodos de tratamiento de cánceres con anticuerpos anti-PD-1
|
KR20190103226A
(ko)
|
2017-01-13 |
2019-09-04 |
아게누스 인코포레이티드 |
Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
CN110461847B
(zh)
|
2017-01-25 |
2022-06-07 |
百济神州有限公司 |
(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
|
CA3052523A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof
|
WO2018144999A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
EP3580230A1
(en)
|
2017-02-07 |
2019-12-18 |
VIB vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
EP3582855A1
(en)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
JP2020509009A
(ja)
|
2017-02-27 |
2020-03-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
キナーゼ阻害剤としての複素環式アミド
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
KR20190124750A
(ko)
|
2017-02-28 |
2019-11-05 |
사노피 |
치료적 rna
|
MA49823A
(fr)
|
2017-03-09 |
2021-04-21 |
Genmab As |
Anticorps dirigés contre pd-l1
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
JP7483227B2
(ja)
*
|
2017-03-31 |
2024-05-15 |
東亞合成株式会社 |
Pd-1シグナル配列を有する抗腫瘍ペプチドおよびその利用
|
BR112019017329A2
(pt)
|
2017-04-03 |
2020-04-14 |
Hoffmann La Roche |
imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição
|
CA3055769A1
(en)
|
2017-04-03 |
2018-10-11 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
US11285207B2
(en)
|
2017-04-05 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specifically binding to PD1 and LAG3
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
WO2018195552A1
(en)
|
2017-04-21 |
2018-10-25 |
Sillajen, Inc. |
Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
SI3618863T1
(sl)
|
2017-05-01 |
2023-12-29 |
Agenus Inc. |
Protitelesa proti tigitu in načini uporabe njih
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
WO2018208667A1
(en)
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
MA49144A
(fr)
|
2017-05-18 |
2020-03-25 |
Tesaro Inc |
Polythérapies pour le traitement du cancer
|
CN110740991B
(zh)
|
2017-05-26 |
2023-07-04 |
大鹏药品工业株式会社 |
新型联苯化合物或其盐
|
US11510915B2
(en)
|
2017-05-26 |
2022-11-29 |
Taiho Pharmaceutical Co., Ltd. |
Anti-tumor effect potentiator using novel biphenyl compound
|
CA3065304A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
HUE065242T2
(hu)
|
2017-05-30 |
2024-05-28 |
Bristol Myers Squibb Co |
LAG-3-pozitív tumorok kezelése
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
WO2018222989A1
(en)
|
2017-06-02 |
2018-12-06 |
The Penn State Research Foundation |
Ceramide nanoliposomes, compositions and methods of using for immunotherapy
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
US11572541B2
(en)
|
2017-06-09 |
2023-02-07 |
Providence Health & Services—Oregon |
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
|
CA3066048A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
US11583576B2
(en)
|
2017-06-15 |
2023-02-21 |
Cancer Advances Inc. |
Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
JP2020524694A
(ja)
|
2017-06-22 |
2020-08-20 |
ノバルティス アーゲー |
がんの処置における使用のためのIL−1β結合性抗体
|
CN118307674A
(zh)
|
2017-06-22 |
2024-07-09 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
CA3066518A1
(en)
|
2017-06-26 |
2019-01-03 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
EP3645037A1
(en)
|
2017-06-27 |
2020-05-06 |
Novartis AG |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
WO2019004417A1
(ja)
|
2017-06-30 |
2019-01-03 |
大鵬薬品工業株式会社 |
アザ二環式化合物を用いたがん化学療法
|
CN110896634A
(zh)
|
2017-07-03 |
2020-03-20 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物
|
US20210145771A1
(en)
|
2017-07-03 |
2021-05-20 |
Glaxosmithkline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
KR20200031659A
(ko)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
WO2019027858A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
|
JP2020529421A
(ja)
|
2017-08-04 |
2020-10-08 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
がんの処置のためのPD−1アンタゴニストおよびベンゾ[b]チオフェンSTINGアゴニストの組み合わせ
|
KR20200064062A
(ko)
|
2017-08-04 |
2020-06-05 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
CA3069930A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
Cd8 binding agents
|
WO2019032663A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
PD-1 AND PD-L1 BINDING AGENTS
|
CN111372934B
(zh)
|
2017-08-18 |
2024-04-26 |
科瑞华生物技术有限公司 |
Tg02的多晶型形式
|
CN111278854A
(zh)
|
2017-09-04 |
2020-06-12 |
艾吉纳斯公司 |
与混合谱系白血病(mll)特异性磷酸肽结合的t细胞受体和其使用方法
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
MX2020002612A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Anticuerpos de la proteina de muerte celular programada 1.
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
CA3076515A1
(en)
|
2017-09-30 |
2019-04-04 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
WO2019069270A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
|
JP2020536106A
(ja)
|
2017-10-05 |
2020-12-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Hivの処置に有用なインターフェロン遺伝子の刺激物質(sting)の調節物質
|
CN111182923A
(zh)
|
2017-10-06 |
2020-05-19 |
特沙诺有限公司 |
组合疗法及其用途
|
SG11202003081WA
(en)
|
2017-10-11 |
2020-05-28 |
Aurigene Discovery Tech Ltd |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
US20200239577A1
(en)
|
2017-10-15 |
2020-07-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019089412A1
(en)
|
2017-11-01 |
2019-05-09 |
Merck Sharp & Dohme Corp. |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
JP7378394B2
(ja)
|
2017-11-03 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
Tim-3およびpd-1経路の二重阻害剤
|
JP7378395B2
(ja)
|
2017-11-06 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
免疫調節のためのコンジョイントセラピー
|
JP7369378B2
(ja)
*
|
2017-11-07 |
2023-10-26 |
ジェイファーマ株式会社 |
抗がん剤及びがんを治療するための医薬組成物
|
US11498904B2
(en)
|
2017-11-14 |
2022-11-15 |
Merck Sharp & Dohme Llc |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
|
EP3710444B1
(en)
|
2017-11-14 |
2023-04-12 |
Merck Sharp & Dohme LLC |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
MX2020005692A
(es)
|
2017-12-01 |
2020-09-25 |
Sbi Pharmaceuticals Co Ltd |
Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
BR112020012308A2
(pt)
|
2017-12-19 |
2020-11-24 |
The Rockefeller University |
variantes domínios de igg fc humanos com função de efeito melhorada
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
WO2019125974A1
(en)
|
2017-12-20 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
US20220305127A1
(en)
|
2017-12-21 |
2022-09-29 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
EP3737408A1
(en)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
DK3743447T3
(da)
|
2018-01-23 |
2024-05-27 |
Nextcure Inc |
B7-H4-antistoffer og fremgangsmåder til anvendelse deraf
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
AU2019215031A1
(en)
|
2018-01-31 |
2020-08-20 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
AU2019217875A1
(en)
|
2018-02-06 |
2020-08-20 |
Icahn School Of Medicine At Mount Sinai |
Repeat RNA as biomarkers of tumor immune response
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
WO2019162325A1
(en)
|
2018-02-21 |
2019-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
CA3091502A1
(en)
|
2018-02-23 |
2019-08-29 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-pd-1 antibodies and uses thereof
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
WO2019178269A2
(en)
|
2018-03-14 |
2019-09-19 |
Surface Oncology, Inc. |
Antibodies that bind cd39 and uses thereof
|
EP3769765B1
(en)
|
2018-03-19 |
2024-04-17 |
Taiho Pharmaceutical Co., Ltd. |
Pharmaceutical composition including sodium alkyl sulfate
|
WO2019183499A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
JP7326319B2
(ja)
|
2018-04-03 |
2023-08-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Stingアゴニストとしてのベンゾチオフェン類及び関連する化合物
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US20210198374A1
(en)
|
2018-04-17 |
2021-07-01 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
CA3093715A1
(en)
|
2018-04-19 |
2019-10-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
EP3781687A4
(en)
|
2018-04-20 |
2022-02-09 |
Merck Sharp & Dohme Corp. |
NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
|
WO2019210055A2
(en)
|
2018-04-26 |
2019-10-31 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
WO2019222359A1
(en)
|
2018-05-15 |
2019-11-21 |
Duke University |
Systems and methods for genetic manipulation of akkermansia species
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
US11352320B2
(en)
|
2018-05-31 |
2022-06-07 |
Merck Sharp & Dohme Corp. |
Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
EP3810109A4
(en)
|
2018-05-31 |
2022-03-16 |
Peloton Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING CD73
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Bcmaに対する結合分子及びその使用
|
SG11202100208VA
(en)
|
2018-07-09 |
2021-02-25 |
Precigen Inc |
Fusion constructs and methods of using thereof
|
JP2021529814A
(ja)
|
2018-07-09 |
2021-11-04 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
化学化合物
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
FI3820573T3
(fi)
|
2018-07-10 |
2023-11-01 |
Novartis Ag |
3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa
|
US20210301020A1
(en)
|
2018-07-24 |
2021-09-30 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
CN112955221A
(zh)
|
2018-08-27 |
2021-06-11 |
皮里斯制药有限公司 |
包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
US20210340279A1
(en)
|
2018-08-31 |
2021-11-04 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
WO2020067170A1
(ja)
|
2018-09-25 |
2020-04-02 |
国立研究開発法人国立循環器病研究センター |
抗腫瘍効果増強剤
|
US20210379129A1
(en)
|
2018-10-09 |
2021-12-09 |
Biocomo Incorporation |
Anticancer agent, pharmaceutical composition for cancer treatment, and kit
|
CA3115802A1
(en)
|
2018-10-17 |
2020-04-23 |
Biolinerx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|
BR112021007517A2
(pt)
|
2018-10-22 |
2021-10-26 |
Glaxosmithkline Intellectual Property Development Limited |
Dosagem
|
JP2022513400A
(ja)
|
2018-10-29 |
2022-02-07 |
メルサナ セラピューティクス インコーポレイテッド |
ペプチド含有リンカーを有するシステイン操作抗体-薬物コンジュゲート
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
WO2020092183A1
(en)
|
2018-11-01 |
2020-05-07 |
Merck Sharp & Dohme Corp. |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
CA3118789A1
(en)
|
2018-11-06 |
2020-05-14 |
Genmab A/S |
Antibody formulation
|
US20210403469A1
(en)
|
2018-11-06 |
2021-12-30 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
CA3119161A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
PT3880186T
(pt)
|
2018-11-14 |
2024-05-28 |
Regeneron Pharma |
Administração intralesional de inibidores de pd-1 para o tratamento do cancro de pele
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
EP3880202A2
(en)
|
2018-11-16 |
2021-09-22 |
ArQule, Inc. |
Pharmaceutical combination for treatment of cancer
|
EP3883969A4
(en)
|
2018-11-19 |
2022-11-16 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
ANTI-PD-1 ANTIBODIES AND THEIR USES
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
CN113015530A
(zh)
|
2018-11-20 |
2021-06-22 |
默沙东公司 |
取代的氨基三唑并嘧啶和氨基三唑并吡嗪腺苷受体拮抗剂、药物组合物及其用途
|
WO2020106560A1
(en)
|
2018-11-20 |
2020-05-28 |
Merck Sharp & Dohme Corp. |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
EP3886845A4
(en)
|
2018-11-28 |
2022-08-10 |
Merck Sharp & Dohme Corp. |
NEW SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
|
JP7406556B2
(ja)
|
2018-11-30 |
2023-12-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Hiv療法に有用な化合物
|
MX2021006329A
(es)
|
2018-11-30 |
2021-08-11 |
Merck Sharp & Dohme Llc |
Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso.
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
MX2021006831A
(es)
|
2018-12-11 |
2021-07-02 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de alk5.
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
BR112021011874A2
(pt)
|
2018-12-20 |
2021-09-08 |
Novartis Ag |
Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
US20220056123A1
(en)
|
2018-12-21 |
2022-02-24 |
Novartis Ag |
Use of il-1beta binding antibodies
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
BR112021012066A2
(pt)
|
2018-12-21 |
2021-11-03 |
Onxeo |
Novas moléculas de ácido nucleico conjugadas e seus usos
|
SG11202104699TA
(en)
|
2018-12-21 |
2021-07-29 |
Novartis Ag |
Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
KR20210106531A
(ko)
|
2018-12-21 |
2021-08-30 |
에임 이뮤노테크 인코포레이티드 |
암 치료를 위한 조성물 및 방법
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
CN109593135B
(zh)
*
|
2018-12-29 |
2021-01-15 |
百奥赛图江苏基因生物技术有限公司 |
抗人pd-l1单克隆抗体及其应用
|
CN111423510B
(zh)
|
2019-01-10 |
2024-02-06 |
迈威(上海)生物科技股份有限公司 |
重组抗人pd-1抗体及其应用
|
WO2020150320A1
(en)
|
2019-01-17 |
2020-07-23 |
Georgia Tech Research Corporation |
Drug delivery systems containing oxidized cholesterols
|
KR20200089645A
(ko)
|
2019-01-17 |
2020-07-27 |
오토텔릭바이오 주식회사 |
암 치료용 조성물
|
CN113366316A
(zh)
|
2019-01-30 |
2021-09-07 |
国家医疗保健研究所 |
用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物
|
CN113924317A
(zh)
|
2019-02-01 |
2022-01-11 |
葛兰素史克知识产权开发有限公司 |
贝兰他单抗莫福汀与派姆单抗组合用于治疗癌症
|
WO2020161083A1
(en)
|
2019-02-04 |
2020-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
US20220098674A1
(en)
|
2019-02-13 |
2022-03-31 |
Inserm (Institut National De La Santé Et Dr La Recherch Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
CN113329792B
(zh)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
CN113490528A
(zh)
|
2019-02-15 |
2021-10-08 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
MA55084A
(fr)
|
2019-02-28 |
2022-01-05 |
Regeneron Pharma |
Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
|
CN113677707A
(zh)
|
2019-03-06 |
2021-11-19 |
瑞泽恩制药公司 |
用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
US11712433B2
(en)
|
2019-03-22 |
2023-08-01 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
SG11202110449YA
(en)
|
2019-03-26 |
2021-10-28 |
Univ Michigan Regents |
Small molecule degraders of stat3
|
CN113767115A
(zh)
|
2019-03-28 |
2021-12-07 |
奥里尼斯生物科学股份有限公司 |
治疗性干扰素α1蛋白
|
WO2020205467A1
(en)
|
2019-03-29 |
2020-10-08 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
KR20220008811A
(ko)
|
2019-03-29 |
2022-01-21 |
엥스띠뛰 퀴리 |
변형된 생물학적 활성을 갖는 인터류킨-2 변이체.
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
EP3963109A1
(en)
|
2019-04-30 |
2022-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020230142A1
(en)
|
2019-05-15 |
2020-11-19 |
Neotx Therapeutics Ltd. |
Cancer treatment
|
CN114302875A
(zh)
|
2019-05-16 |
2022-04-08 |
斯汀塞拉股份有限公司 |
氧代吖啶基乙酸衍生物及使用方法
|
EP3969452A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
EP3976090A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
AU2020283299A1
(en)
*
|
2019-05-29 |
2022-02-03 |
Taiho Pharmaceutical Co., Ltd. |
Combination treatment of cancer using sulfonamide compound and immune regulator
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
CN114269715A
(zh)
|
2019-06-12 |
2022-04-01 |
范德比尔特大学 |
作为氨基酸转运抑制剂的二苄基胺
|
JP2022536419A
(ja)
|
2019-06-12 |
2022-08-16 |
ヴァンダービルト ユニバーシティー |
アミノ酸輸送阻害剤及びその使用
|
WO2020255011A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
WO2020255009A2
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
JP7329173B2
(ja)
|
2019-06-25 |
2023-08-18 |
東亞合成株式会社 |
抗腫瘍ペプチドおよびその利用
|
WO2020261097A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
EP3990635A1
(en)
|
2019-06-27 |
2022-05-04 |
Rigontec GmbH |
Design method for optimized rig-i ligands
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
GB201910138D0
(en)
*
|
2019-07-15 |
2019-08-28 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
EP3999510A1
(en)
|
2019-07-16 |
2022-05-25 |
The Regents Of The University Of Michigan |
Imidazopyrimidines as eed inhibitors and the use thereof
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
US11155567B2
(en)
|
2019-08-02 |
2021-10-26 |
Mersana Therapeutics, Inc. |
Sting agonist compounds and methods of use
|
US20220296705A1
(en)
|
2019-08-09 |
2022-09-22 |
Riken |
Combined use of artificial adjuvant vector cells and an immunostimulant
|
US20220388978A1
(en)
|
2019-08-27 |
2022-12-08 |
Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗cd96抗體及其使用方法
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
KR20220062500A
(ko)
|
2019-09-16 |
2022-05-17 |
서피스 온콜로지, 인크. |
항-cd39 항체 조성물 및 방법
|
CA3151022A1
(en)
|
2019-09-17 |
2021-03-25 |
Bial - R&D Investments, S.A. |
Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
EP4031531A1
(en)
|
2019-09-17 |
2022-07-27 |
Bial-R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
KR20220100860A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
질병의 치료에 사용하기 위한 치환된, 포화 및 불포화 n-헤테로시클릭 카르복사미드 및 관련 화합물
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CA3155010A1
(en)
|
2019-09-19 |
2021-03-25 |
The Regents Of The Universtiy Of Michigan |
Spirocyclic androgen receptor protein degraders
|
EP4034559A1
(en)
|
2019-09-25 |
2022-08-03 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
EP4034562A2
(en)
|
2019-09-27 |
2022-08-03 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigen binding proteins
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
CA3157889A1
(en)
|
2019-10-17 |
2021-04-22 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
JP2022553306A
(ja)
|
2019-10-21 |
2022-12-22 |
ノバルティス アーゲー |
Tim-3阻害剤およびその使用
|
MX2022004766A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Terapias combinadas con venetoclax e inhibidores de tim-3.
|
WO2021078910A1
(en)
|
2019-10-22 |
2021-04-29 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
JP2022554175A
(ja)
|
2019-10-23 |
2022-12-28 |
チェックメイト ファーマシューティカルズ, インコーポレイテッド |
合成rig-i様受容体アゴニスト
|
CN114829357A
(zh)
|
2019-10-28 |
2022-07-29 |
中国科学院上海药物研究所 |
五元杂环氧代羧酸类化合物及其医药用途
|
US20240122938A1
(en)
|
2019-10-29 |
2024-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating uveal melanoma
|
WO2021086909A1
(en)
|
2019-10-29 |
2021-05-06 |
Eisai R&D Managment Co., Ltd. |
Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
|
WO2021092071A1
(en)
|
2019-11-07 |
2021-05-14 |
Oncxerna Therapeutics, Inc. |
Classification of tumor microenvironments
|
EP3824954A1
(en)
|
2019-11-22 |
2021-05-26 |
Centre National de la Recherche Scientifique |
Device, apparatus and method for minibeam radiation therapy
|
AU2020385400A1
(en)
|
2019-11-22 |
2022-06-09 |
Theravance Biopharma R&D Ip, Llc |
Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
US20210154281A1
(en)
|
2019-11-26 |
2021-05-27 |
Massachusetts Institute Of Technology |
Cell-based cancer vaccines and cancer therapies
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
WO2021113679A1
(en)
|
2019-12-06 |
2021-06-10 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
AU2020408198A1
(en)
|
2019-12-19 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
CA3165399A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
KR20220127847A
(ko)
|
2020-01-10 |
2022-09-20 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
뇌암을 치료하기 위해 혈액-뇌 장벽을 통해 면역요법제를 전달하기 위한 방법 및 조성물
|
WO2021144426A1
(en)
|
2020-01-17 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
MX2022008763A
(es)
|
2020-01-17 |
2022-07-27 |
Novartis Ag |
Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
|
WO2021152005A1
(en)
|
2020-01-28 |
2021-08-05 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
CN115038466A
(zh)
|
2020-01-28 |
2022-09-09 |
葛兰素史密斯克莱知识产权发展有限公司 |
联合治疗及其用途和方法
|
BR112022015151A2
(pt)
|
2020-02-04 |
2022-12-20 |
Genmab As |
Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição
|
WO2021156360A1
(en)
|
2020-02-05 |
2021-08-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
US20230113705A1
(en)
|
2020-02-28 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
WO2021195481A1
(en)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
CN115443269A
(zh)
|
2020-03-31 |
2022-12-06 |
施万生物制药研发Ip有限责任公司 |
经取代的嘧啶和使用方法
|
EP4136112A1
(en)
|
2020-04-14 |
2023-02-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
AU2021256925A1
(en)
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
WO2021209357A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
|
EP4139341A1
(en)
|
2020-04-21 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
CN115529818B
(zh)
|
2020-05-01 |
2024-04-02 |
国立大学法人东京大学 |
一种癌的预防或治疗剂、组合医药、以及筛选方法
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
TW202202493A
(zh)
|
2020-05-06 |
2022-01-16 |
美商默沙東藥廠 |
Il4i1抑制劑及使用方法
|
AU2021273009A1
(en)
|
2020-05-13 |
2022-12-15 |
Bonum Therapeutics, Inc. |
Compositions of protein complexes and methods of use thereof
|
US20210354984A1
(en)
|
2020-05-13 |
2021-11-18 |
Massachusetts Institute Of Technology |
Compositions of polymeric microdevices and methods of use thereof in cancer immunotherapy
|
WO2021234110A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
KR20230015954A
(ko)
|
2020-05-26 |
2023-01-31 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
TW202214623A
(zh)
|
2020-06-10 |
2022-04-16 |
美商施萬生物製藥研發 Ip有限責任公司 |
結晶型alk5抑制劑及其用途
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
CN116209459A
(zh)
|
2020-06-26 |
2023-06-02 |
美国安进公司 |
Il-10突变蛋白及其融合蛋白
|
US20230257365A1
(en)
|
2020-07-10 |
2023-08-17 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
WO2022011205A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
US20230266332A1
(en)
|
2020-07-28 |
2023-08-24 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods and compositions for preventing and treating a cancer
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2022046833A1
(en)
|
2020-08-26 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer by administering a pd-1 inhibitor
|
AU2021337223A1
(en)
|
2020-09-02 |
2023-03-16 |
Msd International Gmbh |
Combination therapy of a PD-1 antagonist and an antagonist for VEGFR-2 for treating patients with cancer
|
WO2022051448A1
(en)
|
2020-09-03 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer pain by administering a pd-1 inhibitor
|
CN111920948B
(zh)
*
|
2020-09-25 |
2021-02-02 |
安可瑞(山西)生物细胞有限公司 |
包含免疫细胞的药物组合物用于治疗癌症
|
EP4229090A1
(en)
|
2020-10-16 |
2023-08-23 |
Université d'Aix-Marseille |
Anti-gpc4 single domain antibodies
|
CA3196243A1
(en)
|
2020-10-20 |
2022-04-28 |
Angela Marinetti |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
TW202233185A
(zh)
|
2020-10-28 |
2022-09-01 |
日商衛材R&D企管股份有限公司 |
腫瘤治療用醫藥組合物
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
EP4244392A1
(en)
|
2020-11-16 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for predicting and treating uveal melanoma
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
EP4247352A1
(en)
|
2020-11-18 |
2023-09-27 |
Institut Curie |
Dimers of biguanidines and their therapeutic uses
|
KR20230128482A
(ko)
|
2020-12-07 |
2023-09-05 |
젠맵 에이/에스 |
항체와 탁산의 조합 요법
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
IL304031A
(en)
|
2021-01-14 |
2023-08-01 |
Inst Curie |
Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
|
EP4284919A1
(en)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
WO2022165403A1
(en)
|
2021-02-01 |
2022-08-04 |
Yale University |
Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
US20240190874A1
(en)
|
2021-03-03 |
2024-06-13 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
WO2022187423A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
AU2022242000A1
(en)
|
2021-03-23 |
2023-09-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
AU2022245322A1
(en)
|
2021-03-25 |
2023-10-05 |
Oncxerna Therapeutics, Inc. |
Targeted therapies in cancer
|
BR112023019847A2
(pt)
|
2021-03-29 |
2023-11-07 |
Juno Therapeutics Inc |
Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
US12016860B2
(en)
|
2021-04-08 |
2024-06-25 |
Nurix Therapeutics, Inc. |
Combination therapies with Cbl-b inhibitor compounds
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
MX2023013149A
(es)
|
2021-05-07 |
2023-11-28 |
Surface Oncology Llc |
Anticuerpos anti-il-27 y usos de estos.
|
EP4337763A1
(en)
|
2021-05-10 |
2024-03-20 |
Institut Curie |
Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
EP4346887A1
(en)
|
2021-05-25 |
2024-04-10 |
Edelweiss Immune Inc |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
WO2022256538A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
AU2022288058A1
(en)
|
2021-06-07 |
2023-11-16 |
Agonox, Inc. |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
WO2023278897A1
(en)
|
2021-07-02 |
2023-01-05 |
Yale University |
Compositions and methods for treating cancers
|
AU2022314735A1
(en)
|
2021-07-19 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
|
EP4377348A1
(en)
|
2021-07-30 |
2024-06-05 |
Seagen Inc. |
Treatment for cancer
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
EP4380682A1
(en)
|
2021-08-05 |
2024-06-12 |
Institut Curie |
Scanning dynamic device for minibeams production
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
JPWO2023026881A1
(hu)
|
2021-08-25 |
2023-03-02 |
|
|
AU2022340804A1
(en)
|
2021-08-31 |
2024-03-21 |
Gennao Bio, Inc. |
Compositions and methods for treating cancers
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
KR20240082387A
(ko)
|
2021-10-06 |
2024-06-10 |
젠맵 에이/에스 |
암을 치료하기 위한 항 pd-1 항체와 조합된 pd-l1 및 cd137에 대한 다중특이적 결합제
|
CA3234647A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
AU2022409713A1
(en)
|
2021-12-16 |
2024-06-20 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023159102A1
(en)
|
2022-02-17 |
2023-08-24 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
WO2023174210A1
(en)
|
2022-03-14 |
2023-09-21 |
Laekna Limited |
Combination treatment for cancer
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
WO2023187024A1
(en)
|
2022-03-31 |
2023-10-05 |
Institut Curie |
Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
|
WO2023194607A1
(en)
|
2022-04-07 |
2023-10-12 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
|
WO2023194608A1
(en)
|
2022-04-07 |
2023-10-12 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
TW202412757A
(zh)
|
2022-05-27 |
2024-04-01 |
美商 Viiv 醫療保健公司 |
用於hiv治療之化合物
|
WO2024003353A1
(en)
|
2022-07-01 |
2024-01-04 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024040264A1
(en)
|
2022-08-19 |
2024-02-22 |
Massachusetts Institute Of Technology |
Compositions and methods for targeting dendritic cell lectins
|
WO2024056716A1
(en)
|
2022-09-14 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
WO2024068617A1
(en)
|
2022-09-26 |
2024-04-04 |
Institut Curie |
Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
WO2024112867A1
(en)
|
2022-11-23 |
2024-05-30 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|